Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Cl
-ECHELON-2 Trial Represents Key Component of Late-Stage Clinical Development...
2016-11-10
文传商讯
New European study highlights differing priorities in physician’s ther
Data showed that 60% of physicians prioritised factors related to maintainin...
2016-11-10
文传商讯
Takeda to Present Broad Range of Clinical Data During 58th American Soc
– Demonstrating Expertise and Leadership in Hematologic Oncology, Pres...
2016-11-07
文传商讯
Takeda Showcases Continued Commitment in Hodgkin Lymphoma During 10th I
–Presentations highlight a range of scientific updates on ADCETRIS (brentux...
2016-10-20
文传商讯
Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Exten
Open-label extension of TOUCHSTONE study of ozanimod showed continued sympto...
2016-10-18
文传商讯
Oral GED-0301 Phase 1b Results Show Clinical Remission and Endoscopic R
Clinical improvement observed early, with highest clinical response and remi...
2016-10-17
文传商讯
Durvalumab Shows Promising Preliminary Early Data in Lung and Head & Ne
Early data for durvalumab monotherapy in NSCLC and HNSCC show durable respon...
2016-10-11
文传商讯
Phase III nintedanib trial results in patients with metastatic colorect
Significant increase in progression-free survival was observed with nintedan...
2016-10-11
文传商讯
Overall survival data from LUX-Lung 7 head-to-head trial of afatinib ve
A reduction in the risk of death was observed in the LUX-Lung 7 trial for pa...
2016-10-11
文传商讯
New survey reveals 9 out of 10 patients with IPF were happy with how th
However, need for additional information to help patients at IPF diagnosis i...
2016-09-21
文传商讯
